Celgene successfully defends REVLIMID® compound patent against Kyle Bass' IPR petition
Client(s) Celgene Corporation
Jones Day represented Celgene Corporation in successfully defending an IPR petition filed by Coalition for Affordable Drugs VI LLC (CFAD) - a company formed by hedge fund manager Kyle Bass - against U.S. Patent No. 5,635,517, which is listed in the Orange Book for Celgene's REVLIMID® brand drug. Following Celgene's filing of its Patent Owner Preliminary Response, the PTAB denied CFAD's petition in its entirety, finding that CFAD had failed to establish a reasonable likelihood that it would prevail in showing the unpatentability of any claim of the '517 patent.
Coalition for Affordable Drugs VI LLC et al. v. Celgene Corporation, IPR2015-01169 (PTAB)